AL-F-18-LABELED, AL-F-19-LABELED AND GA-68-LABELED GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-ANTAGONISTS FOR IMAGING OF PROSTATE CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 6, 2015
app pub date -
Jan 19, 2015
filing date -
Feb 6, 2014
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present application discloses compositions and methods of synthesis and use of 18F-, 19F- or 68Ga-labeled molecules of use in PET, SPECT and/or MRI imaging of prostate cancer. Preferably, the 18F, 19F or 68Ga is attached to a chelator moiety on a prostate cancer targeting molecule, more preferably a bombesin analog, more preferably a GRPR antagonist, most preferably JMV5132 or JMV4168. The 18F or 19F may form a complex with a group IIIA metal to promote binding to the chelators. The labeled molecules may be used to detect, diagnose and/or image prostate cancer, including metastatic prostate cancer, in vivo.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully